Evidence map›Paper›PMID 40519989›Full record

ArticleBlood vessels, thrombosis & hemostasis2025

Unfolded von Willebrand factor binds protein S and reduces anticoagulant activity.

Martha M S Sim, Molly Y Mollica, Hammodah R Alfar, Melissa Hollifield, Dominic W Chung, Xiaoyun Fu, Siva Gandhapudi, Daniëlle M Coenen, Kanakanagavalli Shravani Prakhya, Dlovan F D Mahmood and 15 more

Abstract read
In one paragraph

Article in Blood vessels, thrombosis & hemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Martha M S SimDepartment of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY.ORCID 0000-0002-6966-1494
Molly Y MollicaBloodworks Northwest Research Institute, Seattle, WA.ORCID 0000-0002-5975-3539
Hammodah R AlfarDepartment of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY.ORCID 0000-0003-4668-4367
Melissa HollifieldDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY.
Dominic W ChungBloodworks Northwest Research Institute, Seattle, WA.
Xiaoyun FuBloodworks Northwest Research Institute, Seattle, WA.
Siva GandhapudiDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY.ORCID 0000-0002-0764-1308
Daniëlle M CoenenDepartment of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY.ORCID 0000-0001-9036-9685
Kanakanagavalli Shravani PrakhyaDepartment of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY.
Dlovan F D MahmoodSaha Cardiovascular Research Center, University of Kentucky, Lexington, KY.
Meenakshi BanerjeeDepartment of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY.ORCID 0000-0002-5139-5861
Chi PengDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY.ORCID 0000-0002-6761-5566
Xian LiSaha Cardiovascular Research Center, University of Kentucky, Lexington, KY.
Alice C ThorntonDivision of Infectious Disease, University of Kentucky, Lexington, KY.
James Z PorterfieldDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY.
Jamie L SturgillDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY.ORCID 0000-0001-8856-3227
Gail A SievertCenter for Clinical and Translational Science, University of Kentucky, Lexington, KY.
Marietta Barton-BaxterCenter for Clinical and Translational Science, University of Kentucky, Lexington, KY.
Ze ZhengDepartment of Medicine, Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0002-4453-224X
Kenneth S CampbellCenter for Clinical and Translational Science, University of Kentucky, Lexington, KY.
Jerold G WoodwardDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY.
José A LópezBloodworks Northwest Research Institute, Seattle, WA.
Sidney W WhiteheartDepartment of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY.ORCID 0000-0001-5577-0473
Beth A GarvyDepartment of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY.ORCID 0000-0002-7756-6921
Jeremy P WoodDepartment of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY.ORCID 0000-0001-5487-852X

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
RESEARCH TRAINING IN HEMATOLOGYT32HL007093 · NHLBI · UNIVERSITY OF WASHINGTON · PI Janis L Abkowitz · 1985 to 2026
$13.9M
Platelet Exocytosis and Endocytosis in Thrombosis and ImmunityR35HL150818 · NHLBI · UNIVERSITY OF KENTUCKY · PI SIDNEY Waldo WHITEHEART · 2020 to 2026
$6.5M
Molecular and Translational Studies in Hematologic DisordersR35HL145262 · NHLBI · BLOODWORKS · PI LOPEZ, JOSE ARON · 2019 to 2024
$6.5M
Protein S Anticoagulant Activity: Biochemical Mechanisms and Structural StudiesR00HL129193 · NHLBI · UNIVERSITY OF KENTUCKY · PI WOOD, JEREMY P · 2018 to 2020
$736k
Protein S Anticoagulant Activity: Biochemical Mechanisms and Structural StudiesK99HL129193 · NHLBI · VERSITI WISCONSIN, INC. · PI WOOD, JEREMY P · 2015 to 2016
$192k
BLRD VA I01 BX003877NCATS NIH HHS UL1 TR001998NCI NIH HHS P30 CA177558NHLBI NIH HHS K99 HL129193NHLBI NIH HHS R00 HL129193NHLBI NIH HHS R35 HL145262NHLBI NIH HHS R35 HL150818NHLBI NIH HHS T32 HL007093
6 · The paper itself

Abstract

The critical plasma anticoagulant protein S (PS) circulates in 2 functionally distinct pools: free (anticoagulant) or bound to complement component 4b-binding protein (C4BP; anti-inflammatory). Acquired free PS deficiency is detected in several viral infections, but its cause is unclear. Here, we used biochemical approaches and human patient plasma samples to identify an interaction between PS and von Willebrand factor (VWF), which causes free PS deficiency and reduced PS anticoagulant activity. We first identified a shear-dependent interaction between PS and VWF by mass spectrometry. Consistently, PS and VWF could be crosslinked together in plasma, and plasma PS and VWF comigrated in gel electrophoresis. The PS/VWF interaction was blocked by and tissue factor pathway inhibitor but not activated protein C, suggesting an interaction with the sex hormone binding globulin region of PS. Microfluidic systems demonstrated that PS stably binds VWF as VWF unfolds under turbulent flow. PS/VWF complexes also localized to platelet thrombi under laminar arterial flow. In thrombin generation-based assays, shearing plasma decreased PS activity, an effect not seen in the absence of VWF. Finally, free PS deficiency in patients with COVID-19 correlated with changes in VWF, but not C4BP, and with thrombin generation. Our data indicate that PS binds to a shear-exposed site on VWF, thus sequestering free PS and decreasing its anticoagulant activity, which would account for the increased thrombin generation potential. Because many viral infections present with free PS deficiency, elevated circulating VWF, and increased vascular shear, we propose that the PS/VWF interaction reported here is a likely contributor to virus-associated thrombotic risk.

Identifiers

PMID40519989
PMCPMC12162048

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.